Prestige BioPharma Limited (950210.KS)

KRW 15050.0

(-4.57%)

Revenue Summary of Prestige BioPharma Limited

  • Prestige BioPharma Limited's latest annual revenue in 2023 was 689.07 Million KRW , up 325.77% from previous year.
  • Prestige BioPharma Limited's latest quarterly revenue in 2023 Q4 was -137.09 Million KRW , down -121.32% from previous quarter.
  • Prestige BioPharma Limited reported a annual revenue of 161.84 Million KRW in annual revenue 2022, down 0.0% from previous year.
  • Prestige BioPharma Limited reported a annual revenue of - KRW in annual revenue 2021, down 0.0% from previous year.
  • Prestige BioPharma Limited reported a quarterly revenue of 643.02 Million KRW for 2023 Q3, up 436.33% from previous quarter.
  • Prestige BioPharma Limited reported a quarterly revenue of -137.09 Million KRW for 2023 Q4, down -121.32% from previous quarter.

Annual Revenue Chart of Prestige BioPharma Limited (2023 - 2017)

Historical Annual Revenue of Prestige BioPharma Limited (2023 - 2017)

Year Revenue Revenue Growth
2023 689.07 Million KRW 325.77%
2022 161.84 Million KRW 0.0%
2021 - KRW 0.0%
2020 - KRW 0.0%
2019 - KRW -100.0%
2018 2.08 Billion KRW 0.0%
2017 - KRW 0.0%

Peer Revenue Comparison of Prestige BioPharma Limited

Name Revenue Revenue Difference
ORIENT BIO Inc. 28 Billion KRW 97.539%
Green Cross Holdings Corporation 2057.93 Billion KRW 99.967%
Green Cross Holdings Corporation 1626.64 Billion KRW 99.958%
Pharmicell Co., Ltd. 56.22 Billion KRW 98.774%
Green Cross Corporation 1626.64 Billion KRW 99.958%
GeneOne Life Science, Inc. 40.2 Billion KRW 98.286%
Celltrion, Inc. 2176.43 Billion KRW 99.968%
Samsung Biologics Co.,Ltd. 3694.58 Billion KRW 99.981%
SK bioscience Co.,Ltd. 369.5 Billion KRW 99.814%
SK Biopharmaceuticals Co., Ltd. 354.89 Billion KRW 99.806%